Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacological and pharmacokinetic properties of JNJ‐40411813, a positive allosteric modulator of the mGlu2 receptor
Hilde Lavreysen, A. Ahnaou, Wilhelmus Drinkenburg, et al.
Pharmacology Research & Perspectives (2014) Vol. 3, Iss. 1
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors
Craig W. Lindsley, Kyle A. Emmitte, Corey R. Hopkins, et al.
Chemical Reviews (2016) Vol. 116, Iss. 11, pp. 6707-6741
Open Access | Times Cited: 166
Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). I. Drugs in preclinical and early clinical development
Meir Bialer, Svein I. Johannessen, Matthias J. Koepp, et al.
Epilepsia (2020) Vol. 61, Iss. 11, pp. 2340-2364
Open Access | Times Cited: 137
Targeting metabotropic glutamate receptors for novel treatments of schizophrenia
James Maksymetz, Sean P. Moran, P. Jeffrey Conn
Molecular Brain (2017) Vol. 10, Iss. 1
Open Access | Times Cited: 121
Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical and early clinical development
Meir Bialer, Svein I. Johannessen, Matthias J. Koepp, et al.
Epilepsia (2018) Vol. 59, Iss. 10, pp. 1811-1841
Open Access | Times Cited: 117
Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia
Eduard Parellada, Patricia Gassó
Translational Psychiatry (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 76
Structure, function and drug discovery of GPCR signaling
Lin Cheng, Fan Xia, Ziyan Li, et al.
Molecular Biomedicine (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 29
Allosteric modulation of G protein-coupled receptor signaling
Siyuan Shen, Chang Zhao, Chao Wu, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 27
International Union of Basic and Clinical Pharmacology. CXI. Pharmacology, Signaling, and Physiology of Metabotropic Glutamate Receptors
Karen J. Gregory, Cyril Goudet
Pharmacological Reviews (2020) Vol. 73, Iss. 1, pp. 521-569
Open Access | Times Cited: 52
Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depression
Justine Kent, Ella Daly, Iva Kezic, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2016) Vol. 67, pp. 66-73
Closed Access | Times Cited: 49
Biased signaling in drug discovery and precision medicine
Ren-Lei Ji, Ya‐Xiong Tao
Pharmacology & Therapeutics (2025), pp. 108804-108804
Closed Access
Preclinical evaluation of the antipsychotic potential of the mGlu2‐positive allosteric modulator JNJ‐40411813
Hilde Lavreysen, Xavier Langlois, Luc Ver Donck, et al.
Pharmacology Research & Perspectives (2015) Vol. 3, Iss. 2
Open Access | Times Cited: 43
Molecular mechanism of positive allosteric modulation of the metabotropic glutamate receptor 2 by JNJ‐46281222
Maarten L. J. Doornbos, Laura Pérez‐Benito, Gary Tresadern, et al.
British Journal of Pharmacology (2015) Vol. 173, Iss. 3, pp. 588-600
Open Access | Times Cited: 43
Activation of mGlu2/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism
Imane Frouni, Adjia Hamadjida, Cynthia Kwan, et al.
Neuropharmacology (2019) Vol. 158, pp. 107725-107725
Closed Access | Times Cited: 38
Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials
Amanda W. Pong, Jonathan Ross, Ivana Tyrlíková, et al.
Expert Opinion on Emerging Drugs (2022) Vol. 27, Iss. 1, pp. 75-90
Closed Access | Times Cited: 20
Discovery and Kinetic Profiling of 7-Aryl-1,2,4-triazolo[4,3-a]pyridines: Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 2
Maarten L. J. Doornbos, José M. Cid, Jordi Haubrich, et al.
Journal of Medicinal Chemistry (2017) Vol. 60, Iss. 15, pp. 6704-6720
Open Access | Times Cited: 35
Current and future pharmacotherapy options for drug-resistant epilepsy
Samia Elkommos, Marco Mula
Expert Opinion on Pharmacotherapy (2022) Vol. 23, Iss. 18, pp. 2023-2034
Closed Access | Times Cited: 16
Synthesis and Pharmacological Characterization of C4β-Amide-Substituted 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1S,2S,4S,5R,6S)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2794193), a Highly Potent and Selective mGlu3 Receptor Agonist
James A. Monn, Steven S. Henry, Steven M. Massey, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 6, pp. 2303-2328
Closed Access | Times Cited: 24
Covalent Allosteric Probe for the Metabotropic Glutamate Receptor 2: Design, Synthesis, and Pharmacological Characterization
Maarten L. J. Doornbos, Xuesong Wang, Sophie C. Vermond, et al.
Journal of Medicinal Chemistry (2018) Vol. 62, Iss. 1, pp. 223-233
Open Access | Times Cited: 23
Efficacy of mGlu2‐positive allosteric modulators alone and in combination with levetiracetam in the mouse 6 Hz model of psychomotor seizures
Cameron S. Metcalf, Brian D. Klein, Misty D. Smith, et al.
Epilepsia (2017) Vol. 58, Iss. 3, pp. 484-493
Open Access | Times Cited: 22
Constitutive activity of the metabotropic glutamate receptor 2 explored with a whole-cell label-free biosensor
Maarten L. J. Doornbos, Ilse Van der Linden, Liesbeth Vereyken, et al.
Biochemical Pharmacology (2018) Vol. 152, pp. 201-210
Open Access | Times Cited: 18
Panic results in unique molecular and network changes in the amygdala that facilitate fear responses
Andrei I. Molosh, Erik T. Dustrude, J. L. Lukkes, et al.
Molecular Psychiatry (2018) Vol. 25, Iss. 2, pp. 442-460
Open Access | Times Cited: 18
mGlu2 Receptor Agonism, but Not Positive Allosteric Modulation, Elicits Rapid Tolerance towards Their Primary Efficacy on Sleep Measures in Rats
A. Ahnaou, Hilde Lavreysen, Gary Tresadern, et al.
PLoS ONE (2015) Vol. 10, Iss. 12, pp. e0144017-e0144017
Open Access | Times Cited: 17
Metabotropic glutamate receptors in GtoPdb v.2023.1
Francine Acher, Giuseppe Battaglia, Hans Bräuner‐Osborne, et al.
IUPHAR/BPS Guide to Pharmacology CITE (2023) Vol. 2023, Iss. 1
Open Access | Times Cited: 5
Allosteric Modalities for Membrane-Bound Receptors: Insights from Drug Hunting for Brain Diseases
Quinn Coughlin, Allen T. Hopper, María‐Jesús Blanco, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 13, pp. 5979-6002
Closed Access | Times Cited: 15
Translational neurophysiological markers for activity of the metabotropic glutamate receptor (mGluR2) modulator JNJ-40411813: Sleep EEG correlates in rodents and healthy men
A. Ahnaou, Peter de Boer, Hilde Lavreysen, et al.
Neuropharmacology (2015) Vol. 103, pp. 290-305
Closed Access | Times Cited: 14
Page 1 - Next Page

Scroll to top